Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Hosted on MSN
Study Suggests Possible Link Between Pfizer COVID-19 Vaccine and Vision-Related Eye Conditions
Public interest has recently turned to the human eye and the Pfizer COVID-19 Vaccine. Two peer-reviewed papers have helped drive the latest debate. One Turkish cohort measured the cornea before and ...
NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...
Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Pfizer said Wednesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 15, encouraging results that could clear the shots for use in middle school students before school ...
The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results